Moderna is set to reduce its global workforce by roughly 10%, aiming for under 5,000 employees by year's end, as it accelerates cost-cutting due to declining COVID-19 vaccine sales. This move is part of a broader plan to cut operating expenses by $1.5 billion by 2027.